Last reviewed · How we verify
Antiren (PIPERAZINE)
Antiren (Piperazine) is a small molecule drug in the piperazine class, originally developed and currently owned by BLULINE. It was FDA approved in 1954 for the treatment of Ascariasis and Enterobiasis. As an off-patent medication, Antiren is available as a generic product from multiple manufacturers. Key safety considerations include the potential for gastrointestinal side effects. Antiren is a commercially available medication for the treatment of parasitic worm infections.
At a glance
| Generic name | PIPERAZINE |
|---|---|
| Sponsor | Bluline |
| Drug class | piperazine |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1954 |
Approved indications
- Ascariasis
- Enterobiasis
Common side effects
Key clinical trials
- Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors (PHASE2)
- Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI (NA)
- [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers (PHASE1)
- A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas (PHASE1,PHASE2)
- RDD1609 as a Treatment for Idiopathic Pruritus Ani (PHASE2)
- Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors (PHASE1)
- Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide (PHASE1)
- Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiren CI brief — competitive landscape report
- Antiren updates RSS · CI watch RSS
- Bluline portfolio CI